ELI LILLY & Co
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
IN
Business Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN, 46285
Mailing Address
LILLY CORPORATE CENTER, INDIANAPOLIS, IN, 46285
Phone
3172762000
Fiscal Year End
1231
EIN
350470950
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
| 4 Insider stock transaction report | February 18, 2026 | View on SEC |
| 4 Insider stock transaction report | February 18, 2026 | View on SEC |
| 4 Insider stock transaction report | February 18, 2026 | View on SEC |
Annual Reports
10-K
February 12, 2026
- Eli Lilly achieved exceptional performance in 2025, driven by robust sales growth, significant profitability, and strategic investments.
- Total revenue reached $50 billion in 2025, a substantial 22.2% increase, primarily driven by product sales.
Insider Trading
STRONG SELL
1 insiders
100 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.